TALUS BIOSCIENCE, INC.
Strategian, an AI-powered drug discovery platform that uses high-throughput functional proteomics (TF-Scan) and machine learning to discover small-molecule inhibitors of transcription factors
- Sector
- Biotech
- Headquarters
- Seattle, WA
- Founded
- 2020
- Latest Form D
- $9.4M, Aug 2024
- Total capital
- $17.9M
- Federal grants
- $8.5M
- 14 awards · 2021–2026
- Rank in peer group#4 of 36
- Private capital raised
- $9.4M
- 1 Form D · last Aug 2024
- 26 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 9 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Deployment of an AI platform to accelerate transcription factor drug development$1M
- Federal grantHealth and Human S · Phase II · Activity-based regulome profiling for the discovery of covalent transcription factor inhibitors$822K
- Private capital raisedForm D · SEC · 1st filing$9.4M
- Federal grantHealth and Human S · Phase II · Simultaneous pharmacological profiling of oncogenic gene fusion proteins in cancer$1M
- Federal grantHealth and Human S · Phase II · Activity-based regulome profiling for the discovery of covalent transcription factor inhibitors$822K
- Federal grantHealth and Human S · Phase I · Deep learning methods to accelerate discoveryof drugs targeting gene regulatory proteins$398K
- Federal grantHealth and Human S · Phase I · Activity-based regulome profiling for the discovery of covalent transcription factor inhibitors$307K
Show 8 earlier federal awards
- Federal grantHealth and Human S · Phase II · Activity-based regulome profiling for the discovery of covalent transcription factor inhibitors$307K
- Federal grantHealth and Human S · Phase II · Simultaneous pharmacological profiling of oncogenic gene fusion proteins in cancer$1M
- Federal grantHealth and Human S · Phase II · Simultaneous pharmacological profiling of oncogenic gene fusion proteins in cancer$1M
- Federal grantHealth and Human S · Phase I · Simultaneous pharmacological profiling of oncogenic gene fusion proteins in cancer$455K
- Federal grantHealth and Human S · Phase I · Illuminating the "dark" kinases - effects on proteome translocation and chromatin binding$334K
- Federal grantHealth and Human S · Phase II · Simultaneous pharmacological profiling of oncogenic gene fusion proteins in cancer$455K
- Federal grantHealth and Human S · Phase I · Illuminating the "dark" kinases - effects on proteome translocation and chromatin binding$334K
- Federal grantNSF · Phase I · SBIR Phase I: Simultaneous In situ Pharmacological Profiling of Gene Regulatory Proteins (GRPs) for Cancer Therapy$256K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
38months
from TALUS BIOSCIENCE, INC.’s first federal award to its first private round.
- First federal award · Jun 2021
- NSF · $256K
- First Form D · Aug 2024
- $9.4M · 1st Form D
- Awards before first raise
- 12 awards
An association in public records, not a cause or a prediction.
Standing among 36 peers
Line = medianBiotech · Platform
- Federal grants#4 · top 11%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Alex FederationExecutive Officer, Director, PromoterNamed in SEC Form D filings
- J. Seth StrattanDirectorNamed in SEC Form D filings
- Lindsay PinoExecutive Officer, DirectorNamed in SEC Form D filings
- Michelle BriscoeExecutive OfficerNamed in SEC Form D filings
- Omri Amirav-DroryDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 9- PendingMethods For Identifying Reactive Functional Cysteines In Nuclear ProteinsUSPTOApplication 18865559
- PendingExtraction Of Nuclear And Chromatin-bound Proteins Using Volatile SaltsUSPTOApplication 19152833
- PendingLectin-assisted Isolation Of Mammalian Cell NucleiUSPTOApplication PCTUS2024014339
Show all 9 patent records
- Methods For Identifying Reactive Functional Cysteines In Nuclear ProteinsOct 2, 2025 · Application 18865559Pending
- Extraction Of Nuclear And Chromatin-bound Proteins Using Volatile SaltsApplication 19152833Pending
- Lectin-assisted Isolation Of Mammalian Cell NucleiApplication PCTUS2024014339Pending
- Extraction Of Nuclear And Chromatin-bound Proteins Using Volatile SaltsApplication PCTUS2024014337Pending
- Methods For Identifying Reactive Functional Cysteines In Nuclear ProteinsApplication PCTUS2023067134Pending
- Extraction Of Nuclear And Chromatin-bound Proteins Using Volatile SaltsApplication 63443216Pending
- Lectin-assisted Isolation Of Mammalian Cell NucleiApplication 63443201Pending
- Lectin-assisted Isolation Of Mammalian Cell NucleiApplication 19152847Pending
- Methods For Identifying Reactive Functional Cysteines In Nuclear ProteinsApplication 63342908Pending
Related companies, and why
- TALUS BIOSCIENCE INCShares a founder: Alexander Federation
- CIBOTS, INC.Similar federal contract value in Biotech · null in contracts
- ORICULA THERAPEUTICS, LLCSimilar federal contract value in Biotech · null in contracts
- Quantum Insights, Inc.Similar federal contract value in Biotech · null in contracts
- Hummingbird Nano, Inc.Similar federal contract value in Biotech · null in contracts
- Upstream BioSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .